Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

References

• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:945–950. doi:10.1093/nar/gkq929
   PubMed Web of Science ®Google Scholar
• Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81–137.10549356
   PubMed Web of Science ®Google Scholar
• Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346–355. doi:10.1126/science.80231578023157
   PubMed Web of Science ®Google Scholar
• Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;14:8424–8429. doi:10.1073/pnas.1431692100
   Web of Science ®Google Scholar
• Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol. 2001;11:353–356. doi:10.1006/scbi.2001.039011562177
   PubMed Web of Science ®Google Scholar
• Sylvanie S, Marie PK, Jean CB, et al. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. OncoTargets Ther. 2013;7:57–68.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu Y, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–2874. doi:10.1200/JCO.2010.33.423521670455
   PubMed Web of Science ®Google Scholar
• Han J, Park K, Kim S, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–1128. doi:10.1200/JCO.2011.36.845622370314
   PubMed Web of Science ®Google Scholar
• Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334. doi:10.1200/JCO.2013.49.021923816960
   PubMed Web of Science ®Google Scholar
• Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12:429–439.25322323
   PubMedGoogle Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. doi:10.1126/scitranslmed.3002003
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol. 2014;4:190. doi:10.3389/fonc.2014.0019025101246
   PubMedGoogle Scholar
• Eng J, Woo KM, Sima CS, et al. Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas. J Thorac Oncol. 2015;10:1713–1719. doi:10.1097/JTO.000000000000067126334752
   PubMed Web of Science ®Google Scholar
• Yu H, Suzawa K, Jordan EJ, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108–3118. doi:10.1158/1078-0432.CCR-17-296129530932
   PubMed Web of Science ®Google Scholar
• Scoccianti C, Vesin A, Martel G, et al. Prognostic value of TP53, KRAS and EGFR mutations in non-small cell lung cancer: the EUELC cohort. Eur Respir J. 2012;40:177–184. doi:10.1183/09031936.0009731122267755
   PubMed Web of Science ®Google Scholar
• Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, et al. TP53Mutation spectrum in smokers and never smoking lung cancer patients. Front Genet. 2016;7:85. doi:10.3389/fgene.2016.0008527242894
   PubMed Web of Science ®Google Scholar
• Canale M, Petracci E, Delmonte A, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23:2195–2202. doi:10.1158/1078-0432.CCR-16-096627780855
   PubMed Web of Science ®Google Scholar
• Vanderlaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer. 2017;106:17–21. doi:10.1016/j.lungcan.2017.01.01128285689
   PubMed Web of Science ®Google Scholar
• Labbé C, Cabanero M, Korpanty GJ, et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017;111:23–29. doi:10.1016/j.lungcan.2017.06.01428838393
   PubMed Web of Science ®Google Scholar
• Jiao X, Qin B, You P, et al. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 2018;123:70–75. doi:10.1016/j.lungcan.2018.07.00330089598
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Cho EK, et al. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget. 2016;7:36311–36320. doi:10.18632/oncotarget.890427121209
   PubMedGoogle Scholar
• Bria E, Pilotto S, Amato E, et al. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget. 2015;6:12783–12795. doi:10.18632/oncotarget.372725904052
   PubMedGoogle Scholar
• Xu Y, Tong X, Yan J, et al. Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms. Transl Oncol. 2018;11:1364–1369. doi:10.1016/j.tranon.2018.08.01030196239
   PubMed Web of Science ®Google Scholar
• Ulivi P, Delmonte A, Chiadini E, et al. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Int J Mol Sci. 2015;16:747–757. doi:10.3390/ijms16010747
   Web of Science ®Google Scholar
• Hou H, Dong L, Zhang C, et al. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. Oncotarget. 2017;8:105072–105080. doi:10.18632/oncotarget.2134929285234
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. J Natl Cancer Inst. 2000;92:205–216. doi:10.1093/jnci/92.3.20510655437
   PubMed Web of Science ®Google Scholar
• Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561. doi:10.1056/NEJMoa07377018094376
   PubMed Web of Science ®Google Scholar
• Molina-Vila MA, Bertran-Alamillo J, Gascó A, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2014;20:4647–4659. doi:10.1158/1078-0432.CCR-13-239124696321
   PubMed Web of Science ®Google Scholar
• Griesinger F, Netchaeva M, Lüers A, et al. P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI. Ann Oncol. 2016;27:416–454. doi:10.1093/annonc/mdw383.32
   Web of Science ®Google Scholar
• Kuiper JL, Hashemi SMS, Thunnissen E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Brit J Cancer. 2016;115(12):1504–1512. doi:10.1038/bjc.2016.37227875527
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol. 2012;13(3):239. doi:10.1016/S1470-2045(12)70140-722285168
   PubMed Web of Science ®Google Scholar
• Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908–3914. doi:10.1158/1078-0432.CCR-06-046216818686
   PubMed Web of Science ®Google Scholar
• Jin KR, Yun JC, Ryoo BY, et al. p53 enhances Gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 2007;67:1163–1169. doi:10.1158/0008-5472.CAN-06-203717283151
   PubMed Web of Science ®Google Scholar
• Kim G, Ouzounova M, Quraishi AA, et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 2015;34:671–680. doi:10.1038/onc.2014.424531711
   PubMed Web of Science ®Google Scholar
• Lee JK, Lee J, Kim S, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35:3065–3074. doi:10.1200/JCO.2016.71.909628498782
   PubMed Web of Science ®Google Scholar
• Peifer M, Lynnette Fernández C, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–1110. doi:10.1038/ng.239622941188
   PubMed Web of Science ®Google Scholar
• Ku BM, Bae YH, Koh J, et al. Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. 2017;8:67526–67537. doi:10.18632/oncotarget.1872828978051
   PubMedGoogle Scholar